Olivier Bonnot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7183707/publications.pdf

Version: 2024-02-01

236612 214527 2,388 61 25 47 citations h-index g-index papers 82 82 82 2952 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Geneââ,¬â \in °Ã f â \in "ââ,¬â \in °Environment Interactions in Autism Spectrum Disorders: Role of Epigenetic Mechanisms. Frontiers in Psychiatry, 2014, 5, 53.	1.3	203
2	Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents. Journal of Clinical Psychopharmacology, 2012, 32, 309-316.	0.7	167
3	Animal Models Relevant to Schizophrenia and Autism: Validity and Limitations. Behavior Genetics, 2007, 37, 61-78.	1.4	153
4	Pain Reactivity and Plasma \hat{l}^2 -Endorphin in Children and Adolescents with Autistic Disorder. PLoS ONE, 2009, 4, e5289.	1.1	127
5	Autism as a Disorder of Biological and Behavioral Rhythms: Toward New Therapeutic Perspectives. Frontiers in Pediatrics, 2015, 3, 1.	0.9	123
6	Recommendations for the detection and diagnosis of Niemann-Pick disease type C. Neurology: Clinical Practice, 2017, 7, 499-511.	0.8	119
7	Are Patients With Schizophrenia Insensitive to Pain? A Reconsideration of the Question. Clinical Journal of Pain, 2009, 25, 244-252.	0.8	104
8	The neuropsychiatry of inborn errors of metabolism. Journal of Inherited Metabolic Disease, 2013, 36, 687-702.	1.7	83
9	Association of adolescent catatonia with increased mortality and morbidity: Evidence from a prospective follow-up study. Schizophrenia Research, 2009, 113, 233-240.	1.1	73
10	Medical and developmental risk factors of catatonia in children and adolescents: A prospective case–control study. Schizophrenia Research, 2012, 137, 151-158.	1.1	72
11	Clinical relevance of chronic catatonic schizophrenia in children and adolescents: Evidence from a prospective naturalistic study. Schizophrenia Research, 2005, 76, 301-308.	1.1	67
12	Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review. Orphanet Journal of Rare Diseases, 2014, 9, 65.	1.2	67
13	Altered circadian patterns of salivary cortisol in low-functioning children and adolescents with autism. Psychoneuroendocrinology, 2014, 50, 227-245.	1.3	66
14	Are impairments of time perception in schizophrenia a neglected phenomenon?. Journal of Physiology (Paris), 2011, 105, 164-169.	2.1	59
15	Electroconvulsive Therapy in Adolescents With the Catatonia Syndrome. Journal of ECT, 2010, 26, 259-265.	0.3	57
16	Multidisciplinary approach of organic catatonia in children and adolescents may improve treatment decision making. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1393-1398.	2. 5	54
17	Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. Child and Adolescent Psychiatry and Mental Health, 2011, 5, 15.	1.2	52
18	Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature. European Journal of Pediatrics, 2016, 175, 9-18.	1.3	50

#	Article	IF	CITATIONS
19	Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Research in Autism Spectrum Disorders, 2013, 7, 167-175.	0.8	43
20	Systematic review of psychiatric signs in Niemann-Pick disease type C. World Journal of Biological Psychiatry, 2019, 20, 320-332.	1.3	38
21	Cerebrotendinous Xanthomatosis Presenting with Severe Externalized Disorder: <i>Improvement After One Year of Treatment with Chenodeoxycholic Acid</i> CNS Spectrums, 2010, 15, 231-237.	0.7	36
22	Maternal Exposure to Lorazepam and Anal Atresia in Newborns: Results from a Hypothesis-Generating Study of Benzodiazepines and Malformations. Journal of Clinical Psychopharmacology, 2001, 21, 456-458.	0.7	36
23	Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Translational Psychiatry, 2019, 9, 274.	2.4	35
24	Secondary psychosis induced by metabolic disorders. Frontiers in Neuroscience, 2015, 9, 177.	1.4	33
25	Children's synchrony and rhythmicity in imitation of peers: Toward a developmental model of empathy. Journal of Physiology (Paris), 2013, 107, 291-297.	2.1	31
26	The hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease. Current Medical Research and Opinion, 2017, 33, 877-890.	0.9	25
27	Does catatonia influence the phenomenology of childhood onset schizophrenia beyond motor symptoms?. Psychiatry Research, 2008, 158, 356-362.	1.7	24
28	Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges. European Child and Adolescent Psychiatry, 2014, 23, 1149-1160.	2.8	23
29	Children and Adolescents with Severe Mental Illness Need Vitamin D Supplementation Regardless of Disease or Treatment. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 157-161.	0.7	22
30	Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): Findings from the International NPC Registry. World Journal of Biological Psychiatry, 2019, 20, 310-319.	1.3	21
31	Lorazepam, fluoxetine and packing therapy in an adolescent with pervasive developmental disorder and catatonia. Journal of Physiology (Paris), 2010, 104, 309-314.	2.1	19
32	Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis. Journal of Inherited Metabolic Disease, 2018, 41, 641-646.	1.7	19
33	A randomized controlled trial of 25 sessions comparing music therapy and music listening for children with autism spectrum disorder. Psychiatry Research, 2020, 293, 113377.	1.7	19
34	Facteurs de risque psychosociaux et troubles psychiatriques des jeunes pris en charge par l'aide sociale à l'enfance et ayant recours à des soins hospitaliers. Neuropsychiatrie De L'Enfance Et De L'Adolescence, 2011, 59, 393-403.	0.1	17
35	Utilisation des antipsychotiques chez l'enfant et l'adolescent. Neuropsychiatrie De L'Enfance Et De L'Adolescence, 2012, 60, 12-19.	0.1	16
36	Self–other recognition impairments in individuals with schizophrenia: a new experimental paradigm using a double mirror. NPJ Schizophrenia, 2018, 4, 24.	2.0	15

#	Article	IF	CITATIONS
37	Incidence of adverse events in antipsychotic-na \tilde{A} -ve children and adolescents treated with antipsychotic drugs: Results of a multicenter naturalistic study (ETAPE). European Neuropsychopharmacology, 2019, 29, 1397-1407.	0.3	14
38	Modulation of Brain \hat{l}^2 -Endorphin Concentration by the Specific Part of the Y Chromosome in Mice. PLoS ONE, 2011, 6, e16704.	1.1	13
39	Management of Adverse Effects of Second-generation Antipsychotics in Youth. Current Treatment Options in Psychiatry, 2014, 1, 84-105.	0.7	12
40	Incidence of adverse events in antipsychotic-na \tilde{A} -ve children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE). BMJ Open, 2016, 6, e011020.	0.8	10
41	PRIAPISM ASSOCIATED WITH SERTRALINE. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 790-791.	0.3	8
42	Influence of socioeconomic status on antipsychotic prescriptions among youth in France. BMC Psychiatry, 2017, 17, 82.	1.1	8
43	Hormonal Risk Factors for Osteoporosis: Different Profile Among Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 719-726.	0.7	7
44	Mobile App for Parental Empowerment for Caregivers of Children With Autism Spectrum Disorders: Prospective Open Trial. JMIR Mental Health, 2021, 8, e27803.	1.7	7
45	In Search of Digital Dopamine: How Apps Can Motivate Depressed Patients, a Review and Conceptual Analysis. Brain Sciences, 2021, 11, 1454.	1.1	7
46	Time perception of simultaneous and sequential events in early-onset schizophrenia. Neurocase, 2016, 22, 392-399.	0.2	6
47	Health Care Trajectories for Children With ADHD in France: Results From the QUEST Survey. Journal of Attention Disorders, 2020, 24, 52-65.	1.5	6
48	De la médiation musicothérapique dans la prise en charge des troubles du spectre autistique chez l'enfantÂ: évaluation, processus et modélisation. La Psychiatrie De L'enfant, 2019, Vol. 62, 147-171.	0.1	6
49	Rationale and protocol for using a smartphone application to study autism spectrum disorders: SMARTAUTISM. BMJ Open, 2016, 6, e012135.	0.8	5
50	Oculomotor Impairments in Developmental Dyspraxia. Cerebellum, 2017, 16, 411-420.	1.4	5
51	Trastornos psiquiátricos secundarios a enfermedades neurometabólicas. Revista Colombiana De PsiquiatrÃa, 2018, 47, 244-251.	0.1	5
52	Early Detection of Neurodevelopmental Disorders of Toddlers and Postnatal Depression by Mobile Health App: Observational Cross-sectional Study. JMIR MHealth and UHealth, 2022, 10, e38181.	1.8	5
53	Characterising the Radio Frequency Plasma Source for Glow Discharge Optical Emission Spectroscopy. ISIJ International, 2002, 42, S101-S105.	0.6	4
54	PHEDRE trial protocol – observational study of the prevalence of problematic use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and analgesics in the French sickle-cell disease population. BMC Psychiatry, 2015, 15, 281.	1.1	4

#	Article	IF	CITATIONS
55	Efficacy, Tolerability, and Acceptance of Long-Lasting Antipsychotics in Children and Adolescents: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 312-327.	0.7	4
56	Efficacy and Safety of Transcranial Electric Stimulation during the Perinatal Period: A Systematic Literature Review and Three Case Reports. Journal of Clinical Medicine, 2022, 11, 4048.	1.0	4
57	The MEOPAeDent trial protocolâ€"an observational study of the Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) effects in paediatric dentistry. BMC Oral Health, 2019, 19, 42.	0.8	3
58	Advocacy for better metabolic monitoring after antipsychotic initiation: based on data from a French health insurance database. Expert Opinion on Drug Safety, 2021, 20, 225-233.	1.0	3
59	Development of a suspicion index for secondary schizophrenia using the Delphi method. Australian and New Zealand Journal of Psychiatry, 2022, 56, 500-509.	1.3	2
60	Psychiatric disorders secondary to neurometabolic disorders. Revista Colombiana De PsiquiatrÃa (English Ed), 2018, 47, 244-251.	0.1	0
61	5.23 A 12-MONTH PROSPECTIVE FOLLOW-UP STUDY OF A NAÃVE PEDIATRIC POPULATION TREATED WITH ANTIPSYCHOTICS (ETAPE STUDY): INCIDENCE RATE OF ADVERSE EVENTS IN FRANCE. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, S252-S253.	0.3	O